Picture of Essex Bio-Technology logo

1061 — Essex Bio-Technology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Development Agreement

July 16 (Reuters) - Essex Bio-Technology Ltd  1061.HK :
    * ESSEX BIO-INVESTMENT AGREED TO FUND MAXIMUM OF US$16.5
MILLION
FOR CLINICAL DEVELOPMENT IN U.S. FDA FIRST PHASE 3 CLINICAL
TRIAL
    * UNDER AGREEMENT, ESSEX BIO-INVESTMENT HAS AN OPTION TO
FUND
FURTHER DEVELOPMENT OF PRODUCT TO MAXIMUM OF US$20 MILLION

Source text for Eikon:  urn:newsml:reuters.com:*:nHKSbbn3vx
Further company coverage:  1061.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Essex Bio-Technology

See all news